Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024533 | 1.00 | EPHX2 (0.41) | EPHX2CCR3ALDH1A1CYP3A4ROCK1 | |
| SCHEMBL4021455 | 1.00 | EPHX2 (0.41) | EPHX2CCR3ALDH1A1CYP3A4ROCK1 | |
| SCHEMBL5831862 | 0.90 | SMN1; SMN2 (0.41) | CCR3ALDH1A1CYP3A4MEN1LMNA | |
| SCHEMBL5867170 | 0.89 | ALDH1A1 (0.41) | EPHX2CCR3ALDH1A1CYP3A4MEN1 | |
| SCHEMBL5832809 | 0.89 | EPHX2 (0.45) | EPHX2CCR3ALDH1A1CYP3A4MEN1 | |
| SCHEMBL4023311 | 0.88 | CCR3 (0.53) | EPHX2CCR3ALDH1A1CYP3A4MEN1 | |
| SCHEMBL5867293 | 0.86 | SIGMAR1 (0.48) | EPHX2CCR3ALDH1A1CYP3A4MEN1 | |
| SCHEMBL2858926 | 0.84 | DRD4 (0.47) | EPHX2CCR3ALDH1A1CYP3A4ROCK1 | |
| SCHEMBL5831904 | 0.84 | DRD4 (0.47) | EPHX2CCR3ALDH1A1CYP3A4ROCK1 | |
| SCHEMBL5833102 | 0.83 | CCR3 (0.42) | CCR3ALDH1A1CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | claimed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | claimed |
| JP-2006504625-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1492537-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | claimed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | claimed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-7560548-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1492537-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | EPHX2 1092/4885CCR3 7/4885ALDH1A1 3130/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | EPHX2 3057/4885CCR3 4181/4885ALDH1A1 1003/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | EPHX2 2255/4885CCR3 239/4885ALDH1A1 1688/4885 |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ARG1, ARG2, NFKBIA | EPHX2 2255/4885CCR3 239/4885ALDH1A1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.